Anixa Biosciences (ANIX) News Today $2.41 -0.17 (-6.59%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Acquires 10,000 SharesJanuary 18 at 6:50 AM | insidertrades.comAnixa biosciences director Lewis Titterton buys shares worth $25,700January 17 at 8:19 PM | msn.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $25,700.00 in StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. bought 10,000 shares of the company's stock in a transaction on Friday, January 17th. The stock was bought at an average cost of $2.57 per share, for a total transaction of $25,700.00. Following the completion of the acquisition, the director now directly owns 922,334 shares of the company's stock, valued at approximately $2,370,398.38. This represents a 1.10 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.January 17 at 4:55 PM | marketbeat.comAnixa Biosciences Leads 3 Promising Penny Stocks On US ExchangesJanuary 17 at 9:50 AM | finance.yahoo.comAnixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires $19,971.35 in StockJanuary 16 at 6:34 AM | insidertrades.comAnixa Biosciences (ANIX) Projected to Post Quarterly Earnings on TuesdayAnixa Biosciences (NASDAQ:ANIX) will be releasing earnings before the market opens on Tuesday, January 21, Financial Modeling Prep reports.January 15 at 10:46 PM | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani Acquires 9,289 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CFO Michael Catelani bought 9,289 shares of the stock in a transaction on Wednesday, January 15th. The shares were bought at an average price of $2.15 per share, for a total transaction of $19,971.35. Following the acquisition, the chief financial officer now owns 44,500 shares in the company, valued at $95,675. The trade was a 26.38 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.January 15 at 4:41 PM | marketbeat.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Buys 43,000 Shares of StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar purchased 43,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 15th. The stock was bought at an average cost of $2.23 per share, with a total value of $95,890.00. Following the completion of the transaction, the chief executive officer now directly owns 559,925 shares of the company's stock, valued at $1,248,632.75. This represents a 8.32 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.January 15 at 4:41 PM | marketbeat.comAnixa Biosciences' (ANIX) "Buy" Rating Reaffirmed at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday.January 14, 2025 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth PlansJanuary 14, 2025 | finance.yahoo.comAnixa Biosciences (NASDAQ:ANIX) Announces Earnings Results, Beats Expectations By $0.02 EPSAnixa Biosciences (NASDAQ:ANIX - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02.January 11, 2025 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 10.3% in NovemberAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 369,000 shares, a decline of 10.3% from the November 15th total of 411,600 shares. Approximately 1.2% of the company's shares are sold short. Based on an average daily volume of 89,100 shares, the short-interest ratio is presently 4.1 days.December 15, 2024 | marketbeat.comAnixa Biosciences: Uncertainty In The Pipeline, Uncertainty In Their Financial OutlookDecember 10, 2024 | seekingalpha.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Shares Could Be 20% Below Their Intrinsic Value EstimateDecember 4, 2024 | uk.finance.yahoo.comAnixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10December 4, 2024 | prnewswire.comAnixa Biosciences board approves purchase of Bitcoin as treasury reserve assetNovember 23, 2024 | markets.businessinsider.comAnixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve AssetNovember 22, 2024 | prnewswire.comAnixa Biosciences Gains Buy Rating from Yi Chen Amid Promising Cancer Therapy AdvancesNovember 20, 2024 | markets.businessinsider.comAnixa Biosciences' (ANIX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday.November 19, 2024 | marketbeat.comAnixa Biosciences initiates third cohort in CAR-T clinical trialNovember 18, 2024 | markets.businessinsider.comAnixa Biosciences, Inc.: Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical TrialNovember 18, 2024 | finanznachrichten.deAnixa Hikes on TestsNovember 18, 2024 | baystreet.caAnixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical TrialNovember 18, 2024 | prnewswire.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 28.9% in OctoberAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 421,900 shares, a decline of 28.9% from the October 15th total of 593,700 shares. Based on an average daily volume of 75,800 shares, the short-interest ratio is presently 5.6 days. Approximately 1.4% of the company's shares are sold short.November 14, 2024 | marketbeat.comAnixa Biosciences Reports Promising Phase 1 Vaccine ResultsNovember 9, 2024 | markets.businessinsider.comAnixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 8, 2024 | prnewswire.comAnixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 6, 2024 | prnewswire.comAnixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024October 31, 2024 | prnewswire.comAnixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual MeetingOctober 28, 2024 | prnewswire.comAnixa Biosciences administers second CAR-T dose in ovarian cancer trialOctober 16, 2024 | finance.yahoo.comAnixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical TrialOctober 15, 2024 | prnewswire.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 8.9% in SeptemberAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large drop in short interest in September. As of September 30th, there was short interest totalling 627,200 shares, a drop of 8.9% from the September 15th total of 688,800 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average daily volume of 96,300 shares, the short-interest ratio is currently 6.5 days.October 15, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Stock, Short Interest ReportOctober 13, 2024 | benzinga.comAnixa Biosciences (NASDAQ:ANIX) Stock Quotes, Forecast and News SummaryOctober 13, 2024 | benzinga.comPioneering Prevention: Comapny Creates Breast Cancer VaccineOctober 13, 2024 | msn.comAnixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical DevelopmentOctober 7, 2024 | prnewswire.comAnixa Biosciences Announces Submission of Protocol Amendment for CAR-T TrialSeptember 30, 2024 | prnewswire.comAnixa announces plans to launch Phase II breast cancer vaccine trialSeptember 25, 2024 | finance.yahoo.comAnixa Biosciences, Inc.: Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer VaccineSeptember 24, 2024 | finanznachrichten.deAnixa Shares Rise on Plans for Phase 2 Study of Breast Cancer VaccineSeptember 24, 2024 | marketwatch.comAnixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer VaccineSeptember 24, 2024 | prnewswire.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer ConferenceSeptember 18, 2024 | prnewswire.comBuy Rating Affirmed for Anixa Biosciences Amid Promising CAR-T Therapy Trials and Stable FinancialsSeptember 18, 2024 | markets.businessinsider.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Expected to Post FY2024 Earnings of ($0.42) Per ShareAnixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Anixa Biosciences in a research report issued on Monday, September 16th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.42) pSeptember 18, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday.September 17, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Posts Earnings Results, Beats Estimates By $0.01 EPSAnixa Biosciences (NASDAQ:ANIX - Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01.September 9, 2024 | marketbeat.comResearchers developing vaccine that could possibly prevent breast cancerSeptember 6, 2024 | msn.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research SymposiumSeptember 3, 2024 | prnewswire.comAnixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 26, 2024 | prnewswire.comEF Hutton sets stock target on Anixa Biosciences sharesAugust 9, 2024 | uk.investing.com Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIX Media Mentions By Week ANIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIX News Sentiment▼1.190.44▲Average Medical News Sentiment ANIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIX Articles This Week▼142▲ANIX Articles Average Week Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Olema Pharmaceuticals News Neurogene News Rezolute News Atyr PHARMA News Compass Therapeutics News Atea Pharmaceuticals News AC Immune News Canopy Growth News C4 Therapeutics News Candel Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
